Thin layer chromatographic compatibility study in preformulation of new transdermal therapeutic systems

Octavia-Laura Moldovan 1 , Diana-Nicoleta Brihan 1 , Nicoleta Todoran 2  and Aura Rusu 3
  • 1 Faculty of Pharmacy, Romania
  • 2 Pharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, Romania
  • 3 Pharmaceutical Chemistry Department, Faculty of Pharmacy, Romania


Objective: The compatibility of four binary active substances combinations adapalene – levofloxacin (ADP-LFX), adapalene – miconazole nitrate (ADP-MCZ), levofloxacin – meloxicam (LFX-MLX) and levofloxacin – miconazole nitrate (LFX-MCZ) was analysed to be comprised in new transdermal therapeutic systems. Also, the compatibility of selected active substances and four polymeric excipients (hydroxypropyl methyl-cellulose - HPMC 15000, hydroxypropyl methylcellulose - HPMC E5, ethyl cellulose - EC 10, and hydroxyethyl cellulose – HEC) was studied.

Methods: Thin layer chromatographic method (TLC) and four selected mobile phases were used. On the plate (in situ) were obtained the binary combinations (active substances and active substance-polymer).

Results: A good compatibility of ADP-LFX was found using ammonia : methanol : acetonitrile : methylene chloride 2:4:1:4 mobile phase. Using chloroform : acetone : glacial acetic acid 34:4:3 on the chromatogram of ADP-MCZ, only ADP spots appeared but without changes in the shape of the spots and Rf values. Any modifications of LFX and MLX spots (from LFX-MLX mixture) had been observed using toluene : glacial acetic acid : methanol 11:1:0.5 mobile phase, although LFX spots have remained on the baseline. Only LFX spots were visible from LFX-MLX and LFX-MCZ mixtures (ammonia : methanol : acetonitrile : methylene chloride 2:4:1:4 mobile phase). Distinctive spots were observed for ADP, LFX and MLX with variable results from no chemical interactions to limited chemical interactions when the compatibility with polymers was verified.

Conclusions: ADP-LFX and LFX-MLX mixtures were found to be compatible. ADP with HPMC polymers and LFX with HPMC E5 and HEC had presented excellent compatibility; for the other binary combinations, different analytical methods will be necessary.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Srinivasarao K, Sai Adithya B, Teja D, Manikiran S, Ramarao N, An Overview on Preformulation for Pharmaceutical Product Development and Drug Excipient Incompatibility Studies. International Journal of Pharma and Chemical Research. 2017;3:354-368.

  • 2. Vizserálek G, Berkó S, Tóth G, Balogh R, Budai-Szűcs M, Csányi E, et al. Permeability Test for Transdermal and Local Therapeutic Patches Using Skin PAMPA Method. Eur J Pharm Sci. 2015; 30:165-172.

  • 3. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010;1:109-131.

  • 4. Feneran AN, Kaufman WS, Dabade TS, Feldman SR. Retinoid plus antimicrobial combination treatments for acne. Clin Cosmet Investig Dermatol. 2011;4:79-92.

  • 5. Kobayashi M, Nakagawa T, Fukamachi K, Nakamura M, Tokura Y. Efficacy of combined topical treatment of acne vulgaris with adapalene and nadifloxacin: a randomized study. J Dermatol. 2011;38:1163-1166.

  • 6. Takigawa M, Tokura Y, Shimada S, Furukawa F, Noguchi N, Ito T. Acne Study Group. Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris. J Dermatol. 2013;40:620-625.

  • 7. Kawada A, Wada T, Oiso N. Clinical effectiveness of once-daily levofloxacin for inflammatory acne with high concentrations in the lesions. J Dermatol. 2012;39:94-96.

  • 8. Prajapati SK, Kumar S, Singh A, Singh A. Development and characterization of topical microemulsion of levofloxacin, World J Pharm Pharm Sci. 2013;2:5935-5947.

  • 9. Jakeer Hassan SK, Meena T, Lakshmi Durga T, Shahanaj SK. Formulation and evaluation of levofloxacin ointment. International Journal of Pharmaceutical Sciences and Research. 2015;6:3067-3075.

  • 10. Shtanyuk YA. Analysis of antibacterial activity of ointments with levofloxacin and decametoxine on clinical strains agents of wound infections. World of Medicine and Biology. 2015;52:74-77.

  • 11. Mesquita-Guimaraes J, Ramos S, Tavares MR, Carvalho MR. A double-blind clinical trial with a lotion containing 5% benzoyl peroxide and 2% miconazole in patients with acne vulgaris. Clin Exp Dermatol. 1989;14:357-360.

  • 12. Flagothier C, Vroome V, Borgers M, Wang X, Cauwenbergh G, Piérard GE. Effect of a single overnight topical application of miconazole nitrate paste on acne papules. Int J Dermatol. 2006;45:316-319.

  • 13. Fatemi F, Najafian J, Nasab SS, Nilforoushzadeh MA. Treatment of Acne Vulgaris Using the Combination of Topical Erythromycin and Miconazole, Skin Stem Cell. 2014;1:e23330.

  • 14. Hori S, Kizu J, Kawamura M. Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J Infect Chemother. 2003;9:314-320.

  • 15. Dumka VK, Singh H, Srivastava AK. Disposition kinetics and urinary excretion of levofloxacin on concomitant administration with meloxicam in cross-bred calves. Environ Toxicol Pharmacol. 2008;26:56-60.

  • 16. Khan AM, Rampal S, Sood NK. Effect of repeated oral administration of levofloxacin, enrofloxacin, and meloxicam on antioxidant parameters and lipid peroxidation in rabbits. Hum Exp Toxicol. 2017;36:42-50.

  • 17. Meyyanathan SN, Ramasarma GVS, Suresh B. Analysis of Levofloxacin in Pharmaceutical Preparations by High Performance Thin Layer Chromatography. J Sep Sci. 2003;26:1698-1700.

  • 18. Agrawal OD, Shirkhedkar AA, and Surana S.J. Simultaneous Determination of Levofloxacin Hemihydrate and Ambroxol Hydrochloride in Tablets by Thin-Layer Chromatography Combined with Densitometry. J Anal Chem. 2010;65:418-422.

  • 19. Rusu A. Merdar M. Hancu G. Gyéresi Á. Thin-layer chromatographic study regarding the separation of some quinolone derivatives. Medicine in evolution. 2011;XVII:61-65.

  • 20. Hopkała H, Pomykalski A. TLC Analysis of Inhibitors of Cyclooxygenase and Videodensitometric Determination of Meloxicam and Tiaprofenic Acid. JPC. 2003;16:107-111.

  • 21. Shaji, J, Varkey D. Development of a validated stability-indicating HPTLC method for determination of meloxicam in bulk and pharmaceutical formulations: pertinence to ICH guidelines. Int J Pharm Pharm Sci. 2012;4:160-169.

  • 22. Starek M, Krzek J. TLC Determination of Meloxicam in Tablets and after Acidic and Alkaline Hydrolysis. Acta Pol Pharm. 2012;69:225-235.

  • 23. Indrayanto G, Widjaja S, Sutiono S. Simultaneous Densitometric Determination of Betamethasone Valerate and Miconazole Nitrate in Cream, and Its Validation. 1999;22:143-152.

  • 24. Council of Europe, European Pharmacopoeia 9.7, 9th Edition, Council of Europe, Strasbourg, 2018, 6643

  • 25. Wall PE, Thin-layer Chromatography, A Modern Practical Approach, RSC Chromatography Monographs, Cambridge UK, 2005, 86-100

  • 26. Bhatia G, Zhou Y, Banga AK. Adapalene microemulsion for transfollicular drug delivery. J Pharm Sci. 2013;102:2622-2631.

  • 27. Shroot B., Michel S. Pharmacology and Chemistry of Adapalene. J Am Acad Dermatol. 1997;36:S96-103.

  • 28. Modi PB, Shah NJ. Novel Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Clindamycin Phosphate and Adapalene along with Preservatives in Topical Gel Formulations. Sci Pharm. 2014;82:799–813.

  • 29. Roy C, Panigrahi L, Chakrabarty J. Validated Stability-Indicating RP-HPLC Method for the Estimation of Degradation Behaviour of Organic Peroxide and Third-Generation Synthetic Retinoids in Topical Pharmaceutical Dosage Formulation. Sci Pharm. 2015;83:321–338.

  • 30. Chadha R, Bhandari S. Drug-excipient compatibility screening-role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal. 2014;87:82-97.


Journal + Issues